Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer is a phase 1/2, randomised interventional study registered as NCT05503888 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with a registry enrolment figure of 160 participants, started 2022-10-01 and due to reach its primary completion in 2027-07-30. Interventions recorded: Almonertinib combined with SHR-1701; Almonertinib. Conditions listed: Relapsed or Advanced Non-small Cell Lung Cancer. Primary outcome: Dose limiting toxicity （Phase Ib）; The incidence and severity of ≥ grade 3 treatment-related adverse events (TRAE) and serious adverse events (TRSAE) in the combination of two drugs （Phase Ib）; PFS rate at 12 months. Lung eligibility wording from the registry: "Advanced NSCLC diagnosed by histology or cytology, or recurrent NSCLC after radical treatment such as surgery, radiotherapy, chemoradiotherapy". No results are recorded here; the registry entry is the source.